Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non small cell lung cancer without tumor PD L1 expression: A pooled analysis of 3 randomized controlled trials
Pembrolizumab plus platinum based chemotherapy has demonstrated improved clinical outcomes over chemotherapy alone in patients with previously untreated advanced/metastatic non small cell lung cancer (NSCLC) regardless of tumor programmed death ligand 1 (PD L1) expression. This study pooled data from 3 randomized controlled trials to evaluate outcomes with pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced/metastatic NSCLC negative for PD L1 (ie, a tumor proportion score 1%
Cancer